

PHARMACY AND THERAPEUTICS COMMITTEE

DATE: February 14, 2013
 LOCATION: Private Dining Room

CALLED TO ORDER: 7:00 A.M.
 ADJOURNED: 7:56 A.M.

| Members Present: | Members Absent: | Guests: | |
|---|--|---|----------------------|
| Richard Pesce, M.D. Mark Anderson, M.D. Allen Atchley, M.D. David Dodson, M.D. Nathan Schatzman, M.D. Michael Stipanov, M.D. | Vickie Burger, Lab Rodney Elliott, CPt Patrick Ellis, Pharm.D. Patrick Hagan, Finance Lila Heet, Pharm.D. Brian Jones, RD, LDN Elvie Smith, RN Sandy Vredevel, DPh Hannah Walker, RN | Nathan Chamberlain, M.D. Samuel Currin, M.D. Oellerich, M.D. Karen Babb, Pharm.D. Diona Brown, RN,C.N.O Deb Moore, RN, SVP Keith Lockwitz, RN Nan Payne, RN William Melissa Roden, RN Beverly Slate, Supply Chain Gwen Davis, RN | John Jantz, Pharm.D. |

This meeting will be convened under the protection of the Tennessee Statute 63-6-219 and the Health Care Quality Improvement Act of 1986, Public Law 99-660. All information, case reviews, meeting minutes, statistics and correspondence are confidential and protected. Included in that protection are those that are involved in the review of the information. Any discussion of this information outside the realm of Peer Review constitutes a breach and violates the protection of the persons involved in the breach.

| AGENDA ITEM | FINDINGS OR CONCLUSION | ACTION, RESPONSIBILITY | STATUS |
|---|---|---|--|
| Minutes | The February 14, 2013 minutes were approved as submitted. | | Complete |
| Therapeutic Interchanges and Formulary Decisions | <p>The following medications were reviewed:</p> <ol style="list-style-type: none"> Invokana® (canagliflozin) – New agent indicated for the treatment of type 2 diabetes mellitus utilizing a mechanism of action unique from other available agents (increases urinary glucose excretion). Committee recommended delaying formulary approval until more post-marketing data is available. Voted NOT to approve for formulary at this time. Mesalamine formulary review – Asacol® has been removed from the market which has necessitated modifications to the formulary for this class of medications. It was recommended by Gastroenterology to add Lialda® and Delzicol® to formulary and designate Asacol HD® as non-formulary at this time. Pentasa® will remain on formulary and Apriso® will be substituted with Delzicol® per a therapeutic interchange. Topical Anti-virals Formulary Review – Due to recent price increases and limited clinical benefit of the topical anti-virals, it was recommended to designate topical Zovirax® and Denavir® as non-formulary agents. Abreva® will be substituted via a therapeutic interchange when the non-formulary topical agents are ordered. Neupro® (rotigotine) – A topical dopamine receptor agonist used for the treatment of Parkinson’s disease (PD). Formulary addition requested by Dr. Freedman as an alternative for patients unable to take conventional oral PD drugs. Viibryd® (vilazodone) – New oral treatment for major depressive depressive disorder utilizing a unique mechanism of action (SSRI/5-HT1A partial agonist). It was recommended to add to formulary due to its unique mechanism of action to provide continuity of therapy for patients admitted on this treatment as a home medication. Anti-fibrinolytics – Orthopedic surgery – Dr. Bernard is interested in the potential peri-operative use of antifibrinolytics (tranexamic acid, aminocaproic acid) to minimize blood loss associated with total joint replacement surgery. The committee discussed this potential use and was supportive of a trial to examine the potential benefit of decreased blood loss and | <ol style="list-style-type: none"> Not approved. Approved Approved Approved Approved Approved for trial | <p>Complete</p> <p>Complete</p> <p>Complete</p> <p>Complete</p> <p>Complete</p> <p>Pending</p> |

